We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
+19.4%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$4B
AUM Growth
+$287M
Cap. Flow
-$207M
Cap. Flow %
-5.17%
Top 10 Hldgs %
61.89%
Holding
76
New
7
Increased
10
Reduced
7
Closed
6

Top Buys

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$48.1M
2
SNDX icon
Syndax Pharmaceuticals
SNDX
+$28.8M
3
ACIU icon
AC Immune
ACIU
+$23M
4
ETNB
89bio
ETNB
+$20.2M
5
ENGN icon
enGene Therapeutics
ENGN
+$19.9M

Top Sells

Rank Stock Value
1
IDYA icon
IDEAYA Biosciences
IDYA
+$106M
2
IONS icon
Ionis Pharmaceuticals
IONS
+$75.5M
3
PNT
POINT Biopharma Global Inc. Common Stock
PNT
+$70.5M
4
GPCR icon
Structure Therapeutics
GPCR
+$53.7M
5
ACRS icon
Aclaris Therapeutics
ACRS
+$48.4M

Sector Composition

Rank Sector Weight
1 Healthcare 99.98%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ELDN icon
51
Eledon Pharmaceuticals
ELDN
$257M
$7.79M 0.19%
4,326,710
– –
SABS icon
52
SAB Biotherapeutics
SABS
$263M
$6.31M 0.16%
+917,828
New +$7.7M
VIGL
53
DELISTED
Vigil Neuroscience
VIGL
$6.13M 0.15%
1,813,633
– –
CDTX
54
DELISTED
Cidara Therapeutics
CDTX
$5.45M 0.14%
343,056
– –
RAIN
55
DELISTED
Rain Oncology Inc. Common Stock
RAIN
$4.23M 0.11%
3,526,729
– –
DCTH icon
56
Delcath Systems
DCTH
$410M
$4.06M 0.1%
976,149
– –
PVLA
57
Palvella Therapeutics
PVLA
$2.04B
$3.75M 0.09%
257,623
– –
KRON
58
DELISTED
Kronos Bio
KRON
$3.63M 0.09%
2,905,043
– –
NCEL
59
NewcelX Ltd
NCEL
$18.1M
$3.39M 0.08%
14,368
– –
IVA
60
Inventiva
IVA
$1.03B
$3.07M 0.08%
686,040
– –
FBRX icon
61
Forte Biosciences
FBRX
$1.57B
$2.45M 0.06%
119,284
– –
CRVS icon
62
Corvus Pharmaceuticals
CRVS
$1.09B
$2.41M 0.06%
1,370,947
– –
VIRX
63
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$2.06M 0.05%
3,614,662
– –
MTEM
64
DELISTED
Molecular Templates, Inc.
MTEM
$1.97M 0.05%
532,038
– –
UNCY icon
65
Unicycive Therapeutics
UNCY
$138M
$1.84M 0.05%
211,814
-129,542
-38% -$847K
MOLN
66
Molecular Partners
MOLN
$1.76M 0.04%
443,221
– –
ELEV
67
DELISTED
Elevation Oncology
ELEV
$1.24M 0.03%
2,312,200
– –
ENGNW icon
68
enGene Therapeutics Warrants
ENGNW
$3.64M
$804K 0.02%
+945,402
New +$727K
ASLN
69
DELISTED
ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
$548K 0.01%
131,250
– –
RZLT icon
70
Rezolute
RZLT
$449M
$189K ﹤0.01%
190,815
– –
ACRS icon
71
Aclaris Therapeutics
ACRS
$716M
– –
-7,064,736
Closed -$48.4M
IMUX icon
72
Immunic
IMUX
$190M
– –
-114,943
Closed -$1.69M
JSPR icon
73
Jasper Therapeutics
JSPR
$19.1M
– –
-990,000
Closed -$6.93M
REPL icon
74
Replimune Group
REPL
$847M
– –
-2,143,036
Closed -$36.7M
NEUP
75
Neuphoria Therapeutics
NEUP
$21M
– –
-3,948
Closed -$128K
1 2
3
4

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return

BVF Inc's Q4 2023 Portfolio in Review

As of Q4 2023, BVF Inc held 76 positions worth $4B, up 7.7% from $3.71B the previous quarter. Its ten largest holdings account for 62% of the portfolio.

BVF Inc withdrew a net $207M in Q4 2023, closing 6 positions and reducing 7 holdings. Its most notable exit was POINT Biopharma Global Inc. Common Stock, an estimated $70.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier.

Against the trend, BVF Inc opened a new position in Syndax Pharmaceuticals worth $40.5M.

  • BVF Inc's largest Q4 2023 buy was Syndax Pharmaceuticals: 1,875,000 shares worth $40.5M.
  • BVF Inc added most to Revolution Medicines in Q4 2023, an estimated $48.1M increase.
  • BVF Inc's biggest Q4 2023 reduction was IDEAYA Biosciences, cutting an estimated $106M.
  • BVF Inc fully exited POINT Biopharma Global Inc. Common Stock in Q4 2023, selling an estimated $70.5M.
  • BVF Inc's ten largest holdings make up 62% of its $4B portfolio in Q4 2023.
  • BVF Inc opened 7 new positions and closed 6 in Q4 2023.
  • BVF Inc's portfolio value rose 7.7% quarter-over-quarter to $4B.

Based on BVF Inc's 13F filing for Q4 2023, filed 14 Feb 2024.